[This review was originally posted at the Nieman Journalism Lab Cephalexin Price, on Aug. 19, 2011.]

Is social media killing big ideas?: In the New York Times this week, USC fellow Neal Gabler put forward a different form of the familiar "information overload" complaint, this time tying the proliferation of social media to the paucity of big ideas. We don't spend time thinking about and valuing big ideas, Cephalexin from canada, he argued, because we're too busy trying to process — and add to — the flood of information coming at us through social media. You can't think and tweet at the same time, Gabler said, because tweeting "is a form of distraction or anti-thinking."

Naturally, this didn't go over particularly well among the online media punditry. Several people countered that one of Twitter's functions is to direct users to big ideas, no prescription Cephalexin online, to point outside of its 140-character limits through hyperlinks. Media prof Chuck Tryon, author Stephen Baker, and Techdirt's Mike Masnick all made that argument, with Masnick summing it up well: "While social media may not have enlarged Gabler's intellectual universe, it has massively enlarged mine, Cephalexin Price. Thanks to Twitter specifically, I've been able to meet tons of fascinatingly smart people I never would have met otherwise." The trick, as Baker said, is to "listen to the right people, Cephalexin interactions, and then follow their links."

Two other writers made particularly smart points: Kevin Drum of Mother Jones noted that where before we knew exactly where to find big ideas and how to discuss them, we're now in the middle of a massive media transition. That doesn't mean the big idea is dead, he said, it means it's headed somewhere new, and we don't know exactly where yet. And the Lab's Megan Garber pointed out that Gabler's vision of big ideas is closely tied to big media, buy Cephalexin online cod, but argued that those big ideas don't need big media to thrive. Instead, she said, "Increasingly, though, Cephalexin australia, uk, us, usa, the ideas that spark progress are collective, diffusive endeavors rather than the result (to the extent they ever were) of individual inspiration."

—

A paywall plan that understands online readers?: Reuters blogger Felix Salmon is already on record as a supporter of the New York Times' five-month-old paywall, and this week he detailed exactly why he thinks it's so effective. Cephalexin Price, Salmon likened the Times' metered model, with all of its leeway and potential workarounds, to a polite "Please keep off the grass" sign. He argued that contra the prevailing philosophy that readers won't pay for something they can get for free, the Times is betting that "the pleasure of reading its content will be enough to persuade a large number of people to pay. It’s a far more attractive model, and one which is much more likely to attract new young subscribers over the long term."

In a follow-up post, buy cheap Cephalexin, Salmon explained why the Times' model is fundamentally different from the Financial Times' pay meter — it's not trying nearly as hard to keep non-subscribers away from its content. Venture capitalist Fred Wilson and Poynter's Jeff Sonderman agreed with Salmon's premise: Wilson praised the efficacy of getting paid after the fact rather than before, and Sonderman said the Times has discovered that convenience, duty, and appreciation are more compelling motivations than coercion. Cephalexin over the counter, There was one notable dissenter: GigaOM's Mathew Ingram, who took issue with the idea that the Times' plan has been successful, arguing instead that it's not growing the paper's online audience, but setting up digital sandbags to protect a declining print product. The plan "has virtually nothing to do with actually taking advantage of the digital world in any concrete way," Ingram wrote, Cephalexin Price. "It’s just charging people nickels and dimes for their paper, the way the NYT and other newspapers have for a century and a half or so."

—

News Corp.'s problems continue to grow: The damning information against News Corp. in the phone-hacking scandal at its former News of the World newspaper keeps on coming, Cephalexin no rx. This week, it was a four-year-old letter written by Clive Goodman, a reporter at the center of the scandal. In it, Goodman said that the hacking was discussed regularly at the paper and suggested that knowledge of it ran much deeper than News Corp. Cephalexin Price, has been insisting. Ordering Cephalexin online, Notably, News Corp. had submitted the letter to Parliament but redacted the incriminating parts.

With the new revelation, Slate's Jack Shafer wrote that "the scandal has grown too large for one or two willing Murdoch lieutenants or employees to stanch it by taking the fall." That impression has led many watchers to wonder, as the Guardian's Brian Cathcart did, if James Murdoch, Cephalexin recreational, Rupert's son, may be forced to resign. James responded late last week to Parliament's questions about his truthfulness in his testimony to them last month, and News Corp. is reportedly making plans in case he decides to step aside, Cephalexin Price.

The bad news continues to pile up elsewhere in News Corp., Cephalexin photos, too. The private investigator at the center of the scandal sued News International (the company's British newspaper division) for not paying his legal bills, and officially acknowledged in its annual report that the scandal could impair its business, and that it doesn't know how much money it'll end up costing. Two more commentators — the New Yorker's Ken Auletta and Reuters' David Callahan — echoed a popular sentiment lately, saying the responsibility for this whole ordeal lies directly with Rupert Murdoch.

—

Google grabs a mobile-phone producer: For the tech geeks among us, buy Cephalexin online no prescription, Google made some big news this week, buying Motorola Mobility, Motorola's mobile devices division, for $12.5 billion. According to the New York Times Cephalexin Price, , the deal had a lot to do with stockpiling patents in order to defend its Android mobile operating system from patent lawsuits. It also may allow Google to drive down development costs for the all-important smartphone and tablet markets. Order Cephalexin online c.o.d, Cory Bergman of Lost Remote noted that this move isn't just about mobile, though — it also represents Google's biggest move into TV yet. With Motorola's significant share of the cable-TV hardware business, Bergman said, Google now has the opportunity to seamlessly integrate its technology with TVs across the world.

Here at the Lab, Joshua Benton used the acquisition as an example of the tension between a Windows-style modular approach to business, buy Cephalexin without a prescription, with products that can be swapped in and out, and an Apple-esque interdependent one, with a set of interlinking, proprietary products. He also applied the idea to news, saying our journalistic ecosystem needs both the more open modular approach and the more packaged interdependent approach, Cephalexin Price.

A couple of other posts looked at the story of the deal itself: Reuters' Felix Salmon examined the decline (and declining value) of the financial scoops beat, Cephalexin schedule, and Gawker's Ryan Tate saw Google's manufactured press-release quotes by its business partners as a sign that Google is moving away from the "Don't Be Evil" mantra toward being a tight-fisted corporate giant.

—

Reading roundup: This week was a pretty packed one. Here's the best of the rest:

— This week in AOL: The New York Times' Verne Kopytoff analyzed why the new-look AOL has experienced so many hiccups, and j-prof Dan Kennedy seized on the tidbit in that article that AOL would reportedly be profitable without Patch.

— Web philosopher David Weinberger wrote a fantastic piece about the journalistic curiosity and community exchange that's present at Reddit, and GigaOM's Mathew Ingram echoed his thoughts.

— The Knight Digital Media Center's Joy Mayer has apparently become journalism's "Minister of Engagement," and she's earned the title, publishing a thorough guide to community engagement for newsrooms.

— The Online Journalism Review's Robert Niles wondered what journalism is worth, and came up with some depressing answers.

— Finally, since classes are starting up all over the place in the next week or two, here's 10 great tips for journalism students from Sarah Marshall of Journalism.co.uk, via Twitter.

Similar posts: Purchase Synthroid. Synthroid Cost. Lipitor No Rx. Glucophage from canadian pharmacy. Where can i buy cheapest Flagyl online. Glucophage photos.
Trackbacks from: Cephalexin Price. Cephalexin Price. Cephalexin Price. Purchase Cephalexin online. Cephalexin from mexico. Buy Cephalexin online cod.

[This review was originally posted at the Nieman Journalism Lab Diflucan Dosage, on June 10, 2011.]

Apple’s mobile Newsstand is a reality: When Steve Jobs makes an announcement, it’s a pretty good bet that whatever he introduces will be what the media-tech world is talking about for the next week (or month, or year). On Monday, Jobs had plenty to introduce — led by a new Mac operating system (Lion), mobile operating system (iOS 5), and a new cloud service to replace MobileMe (iCloud). Those developments have implications for several different aspects of news and media, Diflucan mg, and I’ll try to run down as many of them as I can.

The most direct impact will likely come from Newsstand, an app Jobs unveiled that will be similar to iBooks, providing a single place for all of a user’s magazine and newspaper app subscriptions.

TechCrunch called it evidence that Apple is emphasizing that the iPad is for reading, while GigaOM’s Mathew Ingram and the Guardian’s Jemima Kiss saw a trade-off for publishers: A simpler subscription interface (which likely means more renewals), but even more control for Apple. For consumers, as the Lab’s Andrew Phelps and Megan Garber noted, purchase Diflucan online no prescription, it’s the closest digital publishing has come to the traditional distribution model of regular home delivery.

Apple’s new operating systems will include a raft of upgrades, many of which overlap with existing third-party apps. The New York Times’ Bits blog has a good breakdown of what apps might be threatened, led by the reading-list creator Instapaper, as Apple will begin offering a similar basic function as part of Safari. Instapaper founder Marco Arment was understandably perturbed by the news, but later reasoned that the upgrade could make saving things to read later a built-in part of the workflow of millions of Apple users — and that if even a small percentage of them want a deluxe version of that service, Instapaper will still be in fine shape. The point was echoed by The Next Web’s Matthew Panzarino and by Andrew and Megan here at the Lab.

—

Apple eases up — kind of: Apple made another significant change this week, too, this one without an announcement, Diflucan Dosage. Order Diflucan online c.o.d, As MacRumors discovered yesterday, Apple quietly adjusted its policy on in-app subscriptions, allowing publishers to sell in-app subscriptions for whatever price they want (previously, they had to be at least as cheap as app subscriptions outside Apple’s store) and lifting the requirement that subscriptions must be offered within the app itself.

All Things Digital’s Peter Kafka has a good explanation of the change, noting that Apple may be allowing companies to circumvent its App Store, but it’s not going to let it be easy. (You still can’t, for example, Diflucan without a prescription, include in your app a “Buy” button pointing users to subscribe via your website.) Still, the lifting of the price restriction could be an encouragement for publishers because, as paidContent’s Staci Kramer pointed out, now they can raise prices to absorb Apple’s 30% revenue cut.

But that doesn’t mean publishers will end up taking advantage of their newfound freedoms. The Lab’s Joshua Benton argued that most publishers won’t, Rx free Diflucan, because customers will resist varied app prices and because Apple’s app purchasing system offers some significant value to publishers that might be worth its 30% cut. And media analyst Ken Doctor reminded us that Apple still holds just about all the cards in this hand.

Poynter’s Jeff Sonderman made an interesting observation: Apple seems to be using the adjusted guidelines to funnel app subscriptions into its new Newsstand. Newsstand’s likely prominence still leaves plenty of open questions for publishers (including the ones outlined earlier), Sonderman said.

—

The Financial Times hedges its bets on Apple: One publisher stated quite emphatically this week that it’s not going to play Apple’s game: The Financial Times unveiled a mobile web app intended as an alternative to Apple’s App Store-based apps.

By using an HTML5-based app, the FT can design a single app for any major mobile device and get around Apple’s 30 percent cut of app subscriptions, but its apps may get pulled from the App Store. Diflucan Dosage, (The next day, the FT responded to Apple’s new guidelines with what sounded like indignation, sounding as though they’ll charge forward.)

An FT exec told the Guardian that the app was something of a line in the sand, resulting from what he called a “Mexican standoff” with Apple. The move was heralded as a critical one in the tug-of-war between Apple and publishers: All Things Digital called it the first attempt by a major news org to create an HTML5 app that feels just like an App Store app, Diflucan street price, and paidContent said the move was “significant and brave,” especially since its Apple-native apps have been so successful.

Bobbie Johnson of GigaOM wondered if this would be the catalyst news orgs need to start standing up to Apple, and Ken Doctor said the FT’s main value would be in providing a counterweight to the Apple-centric market, as well as experiments for other news orgs to learn from. Benedict Evans, Diflucan cost, meanwhile, said the FT may have a dedicated readership to pull this off where other news orgs can’t.

There were a few voices pushing back against the “FT goes to war with Apple” narrative: Noting that the FT says it has no plans of leaving the App Store, the Lab’s Andrew Phelps argued that “FT’s web app could be less about shunning Apple and more about working with it: keeping one foot inside Apple’s garden, and the other outside.” Doctor talked about the FT’s strategy as a blueprint for news orgs to use Apple as Apple uses them.

And both Phelps and Poynter’s Jeff Sonderman noted that the FT’s not the first news org to try this approach, as NPR and others have dabbled in HTML5 apps before. U.K.-based journalist Kevin Anderson reviewed the app and concluded that HTML5 will soon be “the standard that enables the next wave of cross-platform innovation."

—

The metered model gets a closer look: Ever since early last year, when the New York Times announced its plans to charge for its website through a metered model, Diflucan canada, mexico, india, that form of online paid content has gotten far more attention than any other. This week, French media consultant Frederic Filloux offered a useful explainer for the model, detailing how it works, what goes into publishers’ decisions about how to implement them, Online buying Diflucan, and where they fit among other paid-content models. One of its major appeals, he argued, is that advertisers see visitors who have paid up as much more valuable, paying as much as a 30 percent premium to reach them.

Filloux presented the metered model as a way of combating the overreliance on one-time, fly-by web visitors by news sites, Diflucan Dosage. British journalist Kevin Anderson echoed those concerns, calling for news orgs to “move to more honest and realistic metrics” and separate out “bounce” visitors, or those who stay on the site for only a few seconds, from their traffic figures. Meanwhile, Filloux’s metered-model math didn’t sway GigaOM’s Mathew Ingram, Diflucan results, who said he still opposes it as a fundamentally backwards-facing strategy.

Another piece of paid-content news worth noting briefly: Outgoing Fox News personality Glenn Beck’s new Internet broadcast-style network will employ a monthly subscription fee. You can check out the commentary on his venture at Mediagazer.

—

A local reporting crisis: The U.S. Federal Communications Commission added fuel to the long-simmering discussion over the future of accountability reporting in a digital media environment this week, releasing a study finding that the U.S. faces a critical shortage of local reporting, leaving local governmental bodies with an alarming power to influence the news agenda without being checked.

As the Lab’s Megan Garber noted, Diflucan from mexico, its bleak picture of local reporting and many of its proposed solutions were nothing new, except for its recommendation that the government make efforts to funnel advertising into local media, rather than national. Gawker’s Hamilton Nolan said now is a ripe time Diflucan Dosage, for a local news reporting resurgence and urged young reporters to stay away from media centers like New York and flock to small towns instead, and the Atlantic Wire’s Adam Clark Estes looked at how to make that resurgence a reality.

—

A crackup at AOL?: Henry Blodget of Business Insider calculated a tidbit about the post-merger AOL which, if true, is pretty startling: It now has a larger editorial staff than The New York Times. But just because the new, content-oriented AOL is big doesn’t mean it’s stable. A few days earlier, Business Insider published an anonymous note by an AOL staffer painting a picture of a corporate culture marked by paranoia, buy Diflucan no prescription, dissension, and incompetence.

In a more thoroughly reported story, Forbes’ Jeff Bercovici found a similarly grim situation at AOL, revealing a misunderstanding on AOL’s part about how the Huffington Post’s business model works and a dysfunctional sales department, among other problems. Business Insider came back later in the week with a conversation with an anonymous Patch editor who described low morale, Diflucan dose, sagging ad sales, poor leadership and a clueless business model.

Gawker’s Ryan Tate combed through the two pieces for a good, quick rundown of the charges levied against Arianna Huffington, and the Atlantic Wire’s John Hudson also put together a good summary of what’s wrong.

—

Reading roundup: Whew. Here’s what else folks were talking about this week:

— We found out a bit more about the New York Times’ new executive editor, Jill Abramson. Here are profiles and interviews from the New York Observer, get Diflucan, Los Angeles Times, Guardian, Adweek, Low dose Diflucan, and Women’s Wear Daily. Don’t have time for all that, Diflucan Dosage. The Atlantic Wire has a good roundup.

— A new site worth keeping an eye on, especially for sports fans: Grantland, a project of ESPN columnist Bill Simmons, launched this week. Simmons has called it a Miramax to ESPN’s Disney, and former ESPNer Dan Shanoff is optimistic about its chances. Simmons said he’s not into chasing pageviews, and here at the Lab, Tim Carmody looked at Simmons’ effort to find success at the intersection of sports and pop culture.

— Also at the Lab, Justin Ellis took a look at Hacks/Hackers and the future of the niche Q&A site.

— The Knight Digital Media Center’s Amy Gahran suggested the “Lego approach” to storytelling as a way to add context and integration to journalism.

— Finally, one great practical piece and another one to think on. At the Columbia Journalism Review, Craig Silverman got some fantastic tips from various social media experts about how to verify information on social media, and NYU j-prof Jay Rosen took stock of where “pro-am journalism” is and where it’s headed.

Similar posts: Buy Armour No Prescription. Purchase Lipitor. Flagyl Mg. Bactrim photos. Effects of Retin A. Where can i buy Synthroid online.
Trackbacks from: Diflucan Dosage. Diflucan Dosage. Diflucan Dosage. Order Diflucan online overnight delivery no prescription. Diflucan samples. Australia, uk, us, usa.

[This review was originally posted at the Nieman Journalism Lab Purchase Lipitor, on March 18, 2011.]

First reactions to The Times' paid-content plans: Yesterday The New York Times rolled out the online paid-content plans they've been talking about for a little more than a year. You get 20 articles a month for free (besides the ones you get to through Google and social media), and after that it's going to cost you anywhere from $15 to $35 per four weeks, depending on what devices you want to access it on. Print subscribers will get it all for free. (Yup, as the Lab's Josh Benton and Forbes' Jeff Bercovici pointed out, that means there are print plans with online access that are cheaper than the online-only ones.) Subscriptions will sold, Lipitor results, among other places, in Apple's iTunes store. Here's The Times' letter to readers and news article, as well as the Lab's glimpse at the paywall and a good paidContent FAQ.

Now for the reaction and analysis: If you only have time for a few pieces, make them Ken Doctor, Steve Outing, and Felix Salmon, Purchase Lipitor. If you want a quick sampler platter of opinions, you can't do any better than the Lab's roundup of 11 experts' thoughts.

There was no consensus of initial opinion about the plan; many supporters spoke up quickly, including The Times' own media critic, David Carr, purchase Lipitor, and The Daily Beast's Howard Kurtz. Poynter newspaper analyst Rick Edmonds broke down the ways it met all the initial criteria of a sound paywall plan, and British j-prof Paul Bradshaw called it "the most mature, intelligent, and commercially sensible paywall model yet," praising its respect for distribution and online engagement. At The Columbia Journalism Review, Lipitor over the counter, Ryan Chittum said it looked good, and Lauren Kirchner issued a rejoinder to the "information wants to be free" crowd. Purchase Lipitor, The Times' detractors were quick to speak up, too. Media analyst Steve Outing laid out most of the basic objections: The prices are too high, people will turn away when they hit the 20-article limit, and the differentiation by device doesn't make sense. (TechCrunch's Erick Schonfeld harped on the latter point, too.) Reuters' Felix Salmon chimed in by saying that the price point is high enough that a lot of regular readers won't subscribe (meaning the plan won't bring in much revenue anyway), and that the Times is discouraging use of its iPad.

At BoingBoing, Lipitor forum, Cory Doctorow said most users will find the metering system frustrating, leading them to find other ways to read The Times or just not read it at all. Techdirt's Mike Masnick made a similar point, adding that The Times isn't adding any value with the plan. That was tech pioneer Dave Winer's main beef: "They're not offering anything to readers other than the Times' survival, and they're not even explicit about that."

Plenty of commentary didn't fall into either the "pro" or "con" camp, of course, Purchase Lipitor. Here at the Lab, Ken Doctor provided the definitive economic analysis of the plan, breaking down the seven tests it must pass to be successful. Discount Lipitor, Then there was the issue of getting around the paywall (or, as Doctor more accurately called it, the fence): Business Insider told us how to do it via Google, and TechCrunch pontificated on the social media loophole that will develop in addition to the current Google one. Media consultant Steve Yelvington downplayed that factor: "It's not supposed to be a bank vault, people. It's a polite request for payment."

Another obvious next question is whether this could be applied to other news organizations. Purchase Lipitor, Meranda Watling of 10,000 Words compared the plan with those of The Wall Street Journal and Newsday, but Amy Gahran of the Knight Digital Media Center gave other newspapers a stern "don't try this at home."

—

Breaking down an old debate at SXSW: Just as they do every March, geeks descended on Austin, Texas, last weekend for the South by Southwest Interactive Festival, and as usual, there was plenty of journalism-related stuff to chew on, even for those of us who didn't attend. The session that seemed to get the most traction online was NYU professor Jay Rosen's psychological analysis of the tension between bloggers and journalists — which is perhaps a bit surprising for a battle that Rosen himself declared "over" six years ago.

Rosen's whole talk is worth a read, online buy Lipitor without a prescription, but here's the gist of it: For journalists, bloggers are the idealized face of all the ideological and professional stresses they deal with, and for bloggers, the conflict helps keep them on the "outside" of the system, allowing them to maintain their innocence and rhetorical power. Snarkmarket's Matt Thompson and Tim Carmody liveblogged their analysis of the talk, and The Guardian summarized it. Lipitor pics, Michele McLellan of the Knight Digital Media Center ripped blogger-hating journalists for fighting an outdated war, but Melissa Bell of the Washington Post called Rosen's characterization of objectivity misleading.

There were plenty of other panels worth reading about, too, including NYU prof Clay Shirky's timely talk on social media and revolution, in which he said that governments routinely overestimate our access to information and underestimate our access to each other, Purchase Lipitor. (The Guardian had a short summary, and Poynter's Julie Moos put together a blow-by-blow in Storify.)

There were also a couple of panels on the value of gaming, particularly in news, as well as sessions on building trust online, using social media to evade censorship, the future of public media, iPad news apps, is Lipitor safe, and SEO tips from Google and Bing. Poynter's Steve Myers pulled together a dozen journalists for an overview of the conference in terms of building community, and an Economist blogger tied this year's SXSW to last year's with a sharp post questioning the story as the basic unit of journalism.

—

A critical eye on NPR's antagonists: The damage to NPR from James O'Keefe's hidden-camera exposé was already done last week, but the scrutiny of the tape itself didn't begin in earnest until the weekend — kicked off by, of all places, Glenn Beck's website, Lipitor from canada,  The Blaze. (Time's James Poniewozik's breakdown is also worth a read.) The site's skepticism of the video's editing was picked up by NPR media reporter David Folkenflik, who examined the issue in a broadcast report. NPR's spokeswoman called the video Purchase Lipitor, "inappropriately edited," but said the executive in the tape had still made "egregious statements."

Whatever O'Keefe's ethics, Poynter's Steve Myers said, there's plenty he understands about today's media environment that we can learn from: Investigative journalism is in demand, raw media communicates "reality," and soundbites and reducing opponents' logic to absurdities trump context in the online media world.

The change in leadership at NPR prompted others to look at the health and direction of the organization overall: The New York Times' David Carr examined NPR's success in light of the public-funding argument, and Poynter's Mallary Jean Tenore laid out the four biggest challenges for NPR's next CEO. The Lab's Nikki Usher looked overseas for public media comparisons, and The Columbia Journalism Review talked to Jonathan Holmes of the Australian Broadcasting Corporation about the public media situation there.

—

A snapshot of the state of journalism: Pew's Project for Excellence in Journalism released its annual State of the Media report this week, summarizing last year as a good one for journalism. The big headline that most media outlets took away from the study was that for the first time, online news consumption has surpassed newspaper use. There were plenty of other nuggets from the study, though, covering a variety of news media.

The study outlined the state of the newspaper industry, touching on all the major themes from circulation to advertising to digital paid-content efforts, Purchase Lipitor. One of the authors of that part of the study, Poynter's Rick Edmonds, Lipitor overnight,  summarized the trends he found interesting.

It also included a look at the economics of startup community journalism, with discussion of nonprofits, ad-based sites, and the Patch model. (Author Michele McLellan summarized her main points here.) The researchers also reported on a survey on mobile news use, and Amy Gahran of the Knight Digital Media Center and Damon Kiesow of Poynter highlighted some of the opportunities for news organizations in its results.

A couple of other tidbits from the study: Search Engine Land's Vanessa Fox focused on revenue from advertising, subscriptions, Lipitor alternatives, and mobile apps, and j-prof Alfred Hermida pointed out the difference between the news agendas of Twitter, blogs and the mainstream media.

—

Twitter tells developers to hold off: Twitter made waves in the tech world late last week when they posted a note Purchase Lipitor, telling developers not to develop any more Twitter clients, saying they'd like to do it themselves, ostensibly for consistency's sake. (Mashable has a great explanation of the issue.) Most of the initial reaction was not enthusiastic: Salon's Dan Gillmor said the note was a reminder that we need other options for our online platforms that aren't controlled by a single company, and Dave Winer said it reinforces the fact the open web is the best place to develop.

Mathew Ingram of GigaOM and developer Fred Oliveira both urged Twitter to rethink its decision, noting that third-party apps like Tweetdeck and Tweetie spurred much of Twitter's initial growth. Lipitor without prescription, And ReadWriteWeb's Marshall Kirkpatrick saw this as a hint at where Twitter is headed culturally: "If you thought Twitter was a place for outlaws, for free thinkers, for innovators - you need to tuck in your shirt, cut your hair and get a clue."

Others, however, defended Twitter: Social media marketer Jesse Stay said he wishes Twitter had done this a while ago, and developer Rob Diana argued that Twitter has finally given developers a solid sense of direction while still giving them some freedom.

—

Reading roundup: A few notes to digest while your bracket goes up in flames:

— The big news story of the past week has been the earthquake, tsunami and their aftermath in Japan, Lipitor online cod. There wasn't a whole lot written about it from a media perspective, but there were a couple of insightful posts, Purchase Lipitor. Doc Searls looked at coverage and concluded that the web is subsuming TV and radio, and Jeff Jarvis asked for separate Twitter hashtags for breaking news event witnesses.

— A few leftover AOL/Huffington Post items: GigaOM's Mathew Ingram looked at why AOL is desperate for some successful content initiatives, Arianna Huffington talked SEO, TechCrunch broke down the journalism/churnalism tension at AOL, and The New York Times' Bill Keller issued a non-apology followup to his Huffington-bashing essay last week.

— A couple of stray items from the commenting discussion of the last couple of weeks: Via O'Reilly Radar, Effects of Lipitor,  statistics showing the integration of Facebook Comments led to fewer comments at TechCrunch, and a defense of anonymous commenting from Paul O'Flaherty.

— Finally, the Lab has the transcript of an interesting talk Northwestern prof Pablo Boczkowski gave about the gap between what news consumers want and what they get, with a thoughtful response from the Lab's Josh Benton. Enjoy.

Similar posts: Diflucan Cost. Diflucan For Sale. Armour Price. Cipro alternatives. Armour blogs. Diflucan duration.
Trackbacks from: Purchase Lipitor. Purchase Lipitor. Purchase Lipitor. Lipitor results. Lipitor street price. Generic Lipitor.